US equities
|
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
META
$620.19
▼-1.64%
MU
$928.76
▲+2.77%
NVDA
$217.94
▲+0.90%
TSLA
$407.46
▲+4.04%
SPCX
$148.58
▲+1.14%
AAPL
$347.10
▲+0.93%
AMD
$560.26
▲+5.45%
MSFT
$531.33
▼-0.24%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Tyra Biosciences, Inc. - Common Stock
(NQ:
TYRA
)
21.52
+1.10 (+5.39%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tyra Biosciences, Inc. - Common Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
October 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
October 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
September 15, 2026
From
Pomerantz LLP
Via
GlobeNewswire
TYRA Investors Have Opportunity to Join Tyra Biosciences, Inc. Securities Fraud Investigation with the Schall Law Firm
August 20, 2024
From
The Schall Law Firm
Via
Business Wire